Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Head

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
American Journal of Hematology|August 19, 2007
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)Stephen H Petersdorf, Cathryn Rankin, David R Head, et al.
Bone Marrow Research|November 3, 2011
Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesisDavid R Head, James W Jacobberger, Claudio Mosse, et al.
Cancer Research|May 3, 2006
Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosisRobert C Briggs, Keith E Shults, Leanne A Flye, et al.
American Journal of Clinical Pathology|February 26, 2011
Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrowSara A McClintock-Treep, Robert C Briggs, Keith E Shults, et al.
Blood|October 29, 2005
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421David Becton, Gary V Dahl, Yaddanapudi Ravindranath, et al.
Leukemia Research|January 9, 2018
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemiaStephen A Strickland, Aaron C Shaver, Michael Byrne, et al.
Archives of Pathology & Laboratory Medicine|August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
American Journal of Hematology|August 19, 2007
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500)Stephen H Petersdorf, Cathryn Rankin, David R Head, et al.
Bone Marrow Research|November 3, 2011
Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesisDavid R Head, James W Jacobberger, Claudio Mosse, et al.
Cancer Research|May 3, 2006
Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosisRobert C Briggs, Keith E Shults, Leanne A Flye, et al.
American Journal of Clinical Pathology|February 26, 2011
Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrowSara A McClintock-Treep, Robert C Briggs, Keith E Shults, et al.
Blood|October 29, 2005
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421David Becton, Gary V Dahl, Yaddanapudi Ravindranath, et al.
Leukemia Research|January 9, 2018
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemiaStephen A Strickland, Aaron C Shaver, Michael Byrne, et al.
Archives of Pathology & Laboratory Medicine|August 21, 2019
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431Kelley J Mast, Jeffrey W Taub, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Pageof 2